CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) ( K i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC 50 s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1 , HIPK2 ( homeodomain-interacting protein kinase 2 ), and DYRK1A with K i s of 8.65 µM, 15.25 µM, a
Storage Temp
Store at -80°C
Shipped In
Ice chest + Ice pads
Product Description
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) ( K i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC 50 s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1 , HIPK2 ( homeodomain-interacting protein kinase 2 ), and DYRK1A with K i s of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy
In Vitro
CK2/ERK8-IN-1 (Compound K66; 0-50 µM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Jurkat cells Concentration: 0-50 µM Incubation Time: 24 hours Result: Inhibited cell growth in a dose-dependent manner.
